Drug intelligence / Profile preview

iODN2088

Development stage
Preclinical
Lead developer
InvivoGen
Modality
MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intraperitoneal, Subcutaneous
01

Overview

iODN2088 is a synthetic inhibitory oligodeoxynucleotide (iODN) that functions as a potent and specific antagonist of Toll-like receptor 9 (TLR9). It consists of a phosphorothioate-modified sequence that includes a G-rich inhibitory motif, which allows it to competitively bind to TLR9 and prevent the recognition of stimulatory CpG-containing DNA. By blocking TLR9 activation, iODN2088 suppresses the recruitment of MyD88 and the subsequent activation of the NF-κB and MAPK signaling pathways, thereby reducing the production of pro-inflammatory cytokines. While primarily utilized as a research tool to study the role of TLR9 in innate immunity and inflammatory pathologies such as atherosclerosis and autoimmune diseases, it represents a class of molecules with potential therapeutic applications in modulating aberrant immune responses.

Other names
inhibitory ODN 2088TLR9 antagonistTLR-9 antagonistTLR 9 antagonistinhibitory CpG ODN
02

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on iODN2088.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on iODN2088.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call